

**Supplementary Table 2.** Correlation of prevalence of EpCAM/CD49 with breast cancer prognosis (multivariate analysis)

No. (%)	DFS		OS	
	p-value	HR (95% CI)	p-value	HR (95% CI)
EpCAM <sup>+</sup> /CD49f <sup>+</sup> (%)	0.010		0.002	
- (0)	103 (68.7)	1		1
+ (>0)	47 (31.3)	2.070 (1.188–3.608)		3.235 (1.551–6.748)
EpCAM <sup>+</sup> /CD49f <sup>+</sup> (%)	0.061		0.042	
- (0)	110 (73.3)	1		1
+ (>0)	40 (26.7)	1.813 (0.974–3.377)		2.250 (1.031–4.907)
EpCAM <sup>+</sup> /CD49f <sup>-</sup> (%)	0.267		0.455	
- (0)	94 (22.3)	1		1
+ (>0)	56 (77.7)	1.357 (0.792–2.323)		1.308 (0.647–2.646)
EpCAM <sup>-</sup> /CD49f <sup>+</sup> (%)	0.302		0.444	
- (0)	26 (17.3)	1		1
+ (>0)	124 (82.7)	0.713 (0.376–1.351)		0.721 (0.312–1.666)

EpCAM=epithelial cell adhesion molecule; DFS=disease-free survival; OS=overall survival; HR=hazard risk; CI=confidence interval.